Kane Biotech (TSE:KNE) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kane Biotech honors the legacy of the late Dr. Greg Schultz with the launch of the Schultz Biofilm Wound Map, a pioneering in vitro detection kit for biofilms in wound beds. This tool is poised to significantly advance the treatment of chronic wounds and is a testament to Dr. Schultz’s impactful work at Kane Biotech, where he was instrumental in developing key antimicrobial technologies. The company’s commitment to combating biofilm-related problems in healthcare continues with this innovative tribute to their former Chief Science Officer.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.